Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V. (CRXL)
10/8/2012 10:44:12 AM
More...
|
ExpreS2ion Biotechnologies, Mucosis B.V., and University of Copenhagen Receive Eurostars Grant
9/25/2012 10:31:35 AM
More...
|
Mucosis B.V. Appoints Thomas Johnston to CEO
9/17/2012 8:20:38 AM
More...
|
Mucosis B.V. Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
5/10/2012 9:08:13 AM
More...
|
Mucosis B.V. Announces Publication of Preclinical Data Demonstrating Superior Protection by Mucosally Administered Mimopath®-Based Influenza Vaccines
5/3/2012 11:05:11 AM
More...
|
Mucosis B.V. Announces New Scientific Advisory Board
11/15/2011 9:06:34 AM
More...
|
Mucosis B.V. Appoints Thomas Johnston As Chief Business Officer
5/17/2011 10:26:36 AM
More...
|
Mucosis B.V. Starts Clinical Study with its Lead Product, Flugem(TM)
3/21/2011 9:21:23 AM
More...
|
Dr Barry Buckland Joins the Mucosis B.V. Supervisory Board
11/12/2010 10:38:58 AM
More...
|
Mucosis B.V. and Path Sign Agreement to Pursue Mimopath(TM)-Based Oral Diarrhea Vaccines
9/28/2010 12:34:02 PM
More...
|
|